Science and Research

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)

To evaluate the effect of tozorakimab as add on to standard of care compared with standard of care plus placebo on the rate of moderate to severe exacerbations in former smokers.

Study details
Study-ID: 2023-505543-39
Study-ID: 2023-505543-39
DZL Disease Area: COPD
DZL Disease Area: COPD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL on steering board
DZL Role: DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 22.02.2024
Completion Date: 05.02.2025
Status: Active / not recruiting
Status: Active / not recruiting
DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.